ClinicalTrials.gg
RecruitingNCT06943365TRACK-VFUpdated Jun 16, 2026

Role of Anti-TREK-1 Autoantibodies in SCVF

An observational study in Short-coupled Ventricular Fibrillation and Idiopathic Ventricular Fibrillation, sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

Short-coupled ventricular fibrillation (SCVF) is a lethal, primary electrical disorder and an important cause of unexplained cardiac arrest.1 Recent work from our group suggests that a substantial proportion of SCVF cases is associated to circulating autoantibodies targeting TREK-1, a cardiac potassium channel, resulting in an abnormal gain-of-function which is the prerequisite for the SCVF phenotype.2 This proposal is a translational multicenter study to validate anti-TREK-1 autoantibodies as a diagnostic and prognostic biomarker in a large, diversified cohort of SCVF patients (Figure 1). Functional, cellular experiments in patient-derived hiPSC cardiomyocytes and Purkinje cells will be performed to explore the cell type-specific role of TREK-1 in arrhythmogenesis, while single-nuclear RNA sequencing (snRNA-seq) will allow us to establish the transcriptomic profile (Figure 1). These results will identify the cellular substrate for SCVF.

Read the detailed description

Please refer to the uploaded study protocol

02

Conditions studied

  • Short-coupled Ventricular Fibrillation
  • Idiopathic Ventricular Fibrillation

Keywords

  • SCVF
  • anti-TREK-1 antibodies
  • IVF
03

In context

Lead sponsor

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval is the lead sponsor of 15 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cohort study of SCVF probands

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosis of SCVF as per current criteria
  • Willingness to provide written

Exclusion criteria

Exclusion Criteria:

- SCVF patients \< age 18

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • SCVF

    Probands with diagnosis of SCVF

    Other: Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies · Genetic: DPP6 risk haplotype

  • IVF

    Otherwise unexplained idiopathic ventricular fibrillation

    Other: Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies · Genetic: DPP6 risk haplotype

  • Control group

    Unaffected healthy individuals matched for age, sex and ethnicity

    Other: Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies

Interventions

  • OtherRepeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies

    Semiquantitative measure of circulating anti-TREK-1 autoantibodies in plasma of study participants using a peptid microarray

  • GeneticDPP6 risk haplotype

    Systematic genetic screening for the Dutch DPP6 risk haplotype in all study participants and correlation of results with the presence or absence of anti-TREK-1 autoantibodies

06

What researchers measure

Primary outcomes

  1. Presence of anti-TREK-1 autoantibodies at three different time points

    Plasma concentrations of anti-TREK-1 autoantibodies (semiquantitative measure using a peptide microarray at three predefined time points

    Time frame: 12 months

Secondary outcomes

  1. Time-dependent variability of plasma concentrations of anti-TREK-1 autoantibodies

    Repeat plasma sampling to assess the presence/absence of anti-TREK-1 autoantibodies and time-dependent variability of antibody expression

    Time frame: 12 months

  2. Impact of anti-TREK-1 autoantibodies on disease severity

    Correlation of the presence (plasma concentration) of anti-TREK-1 autoantibodies with recurrent VF, electrical storm and appropriate ICD therapies

    Time frame: 12 months

07

Study locations

1 of 5 sites recruiting
  • St-Paul's Hospital - University of British Columbia
    Vancouver, British Columbia, Canada
    Not yet recruiting
    • Andrew D Krahn, MD · Contact
  • PHRI
    Hamilton, Ontario, Canada
    Active, not recruiting

    Not enrolling at this site.

  • Ottawa Heart Center
    Ottawa, Ontario, Canada
    Not yet recruiting
    • Simon Hansom, MD · Contact
  • Institut universitaire de cardiologie et pneumologie de Québec
    Québec, Quebec G1V4G5, Canada
    Recruiting
  • Amsterdam University Medical Center
    Amsterdam, Netherlands
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Publications

  • Steinberg C. Short-Coupled Ventricular Fibrillation. Card Electrophysiol Clin. 2023 Sep;15(3):331-341. doi: 10.1016/j.ccep.2023.05.004. Epub 2023 Jun 18. PubMed 37558303 ↗
  • Steinberg C, Davies B, Mellor G, Tadros R, Laksman ZW, Roberts JD, Green M, Alqarawi W, Angaran P, Healey J, Sanatani S, Leather R, Seifer C, Fournier A, Duff H, Gardner M, McIntyre C, Hamilton R, Simpson CS, Krahn AD. Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry. Eur Heart J. 2021 Jul 31;42(29):2827-2838. doi: 10.1093/eurheartj/ehab275. PubMed 34010395 ↗
  • Li J, Janin A, Patoughi M, Gaudreault N, Kis L, Moha Ou Maati H, Bosse Y, Steinberg C. Circulating Autoantibodies Targeting TREK-1 in Patients With Short-Coupled Ventricular Fibrillation. Circulation. 2024 Dec 10;150(24):1944-1954. doi: 10.1161/CIRCULATIONAHA.124.070284. Epub 2024 Sep 24. PubMed 39315453 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jul 2027, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2025
First posted
Apr 24, 2025
StartActual
May 1, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06943365
Lead sponsor
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Responsible party
Christian Steinberg (MD, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval) — Principal investigator
First posted
Apr 24, 2025
Start date
May 1, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jun 16, 2026

Study contacts

Marina Sanchez, PhD
Contact
marina.sanchez@criucpq.ulaval.ca
+14186568711
Paule Banville, Study coordinator
Contact
paule.banville@criucpq.ulaval.ca
+14186568711
Christian Steinberg, MD
principal investigator · Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion